NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers

T. A. Yap, N. Ngoi, E. E. Dumbrava, D. D. Karp, J. Rodon Ahnert, S. Fu, D. S. Hong, A. Naing, S. Pant, S. A. Piha-Paul, V. Subbiah, A. M. Tsimberidou, D. Dufner, J. Rhudy, S. Gore, S. P. Ivy, Y. Yuan, S. N. Westin, G. B. Mills, F. Meric-Bernstam

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)S7
JournalEuropean Journal of Cancer
StatePublished - Oct 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this